March 21 (Reuters) - Merck ( MRK ) said on Thursday a
combination of its cancer drugs Keytruda and Lynparza failed to
meet the main goals of a late-stage study evaluating it as an
initial treatment for a type of lung cancer.
(Reporting by Puyaan Singh; Editing by Shinjini Ganguli)